Xiaomei Ma, PhD
Professor of Epidemiology (Chronic Diseases)DownloadHi-Res Photo
Cards
Additional Titles
Co-Leader, Cancer Prevention and Control
Contact Info
Chronic Disease Epidemiology
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
About
Copy Link
Titles
Professor of Epidemiology (Chronic Diseases)
Co-Leader, Cancer Prevention and Control
Biography
Dr. Ma is Professor of Epidemiology at the Yale School of Public Health, and Co-Leader of the Cancer Prevention and Control Research Program at the Yale Comprehensive Cancer Center, Yale School of Medicine. She studies the etiology and health outcomes of different types of cancer, including pediatric and early-onset cancers at various sites, as well as malignancies of the hematopoietic and urological systems and of the gastrointestinal tract. Her research has addressed the link between immunological factors, environmental chemical exposures, genetic and metabolomic factors, and cancer risk. In addition, she has assessed the patterns of care with regard to cancer screening, treatment, and survivorship across the age spectrum.
Last Updated on July 23, 2026.
Appointments
Chronic Disease Epidemiology
ProfessorPrimary
Other Departments & Organizations
- Cancer Prevention and Control
- Chronic Disease Epidemiology
- Climate Change and Health
- COPPER Center
- K12 Calabresi Immuno-Oncology Training Program (IOTP)
- Yale Cancer Center
- Yale School of Public Health
- Yale Ventures
Education & Training
- PhD
- University of California at Berkeley, Epidemiology
Research
Copy Link
Overview
Medical Research Interests
Chronic Disease; Epidemiology; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms
Public Health Interests
Aging; Cancer; Chronic Diseases; Health Policy; Maternal & Child Health
ORCID
0000-0001-9472-8032
Research at a Glance
Yale Co-Authors
Frequent collaborators of Xiaomei Ma's published research.
Publications Timeline
A big-picture view of Xiaomei Ma's research output by year.
Research Interests
Research topics Xiaomei Ma is interested in exploring.
Rong Wang, PhD
Nikolai Podoltsev, MD, PhD
Amer Zeidan, MBBS, MD
Scott Huntington, MD, MPH, MSc
Cary P Gross, MD
Nicole Deziel, PhD, MHS
263Publications
9,985Citations
Myelodysplastic Syndromes
Neoplasms
Leukemia
Myeloproliferative Disorders
Chronic Disease
Lymphoma
Publications
2026
Demographic, birth, parental characteristics, and the risk of early‐onset colorectal cancer: A population‐based nested case‐control study in California
Siddique S, Wang R, Berardi D, Johnson C, Wiemels J, Metayer C, Ma X. Demographic, birth, parental characteristics, and the risk of early‐onset colorectal cancer: A population‐based nested case‐control study in California. Cancer 2026, 132: e70458. PMID: 42324895, PMCID: PMC13284631, DOI: 10.1002/cncr.70458.Peer-Reviewed Original ResearchThis study investigates early-onset colorectal cancer, showing male sex, Hispanic ethnicity, high birthweight, and older paternal age increase risk, while foreign-born mothers may reduce it.Helicobacter pylori infection and metabolic dysfunction-associated steatotic liver disease: a prospective study and meta-analysis.
Zhao L, Chen Y, Zhang X, Mezzacappa C, Ma X, Banini B, Lee J, Liu C, Zhang X, Hsing A, Nguyen M, Hyun C, Camargo M, McGlynn K, Hou L, Taddei T, Zhang X. Helicobacter pylori infection and metabolic dysfunction-associated steatotic liver disease: a prospective study and meta-analysis. Cancer Epidemiology Biomarkers & Prevention 2026 PMID: 42233960, DOI: 10.1158/1055-9965.epi-26-0038.Peer-Reviewed Original ResearchAltmetricConceptsH. pylori seropositivityHazard ratioConfidence intervalsCagA seropositivityCross-sectional studyCardiometabolic factorsH. pyloriPrevention strategiesProspective cohortHealth concernMedian Follow-UpMeta-analysisAsian populationsUKBParticipantsHigh riskCox modelH. pylori infectionGlobal health concernFollow-upProspective studyRiskRisk stratificationLiver diseaseSteatotic liver diseaseProstate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer
Leapman M, Rothen J, Long J, Kim I, Mitchell A, Yu J, Dinan M, Gross C, Ma X. Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer. JAMA Oncology 2026, 12 PMID: 42096231, PMCID: PMC13154023, DOI: 10.1001/jamaoncol.2026.0893.Peer-Reviewed Original ResearchThis study investigates how PSMA-PET imaging for prostate cancer leads to earlier use of advanced therapies compared to traditional bone scans, impacting treatment decisions and costs.Immunomodulatory Agent Adherence Trajectories and Survival Among Older Patients With Multiple Myeloma.
Wang R, Ji M, Neparidze N, Ma X, Chang S, Wang S. Immunomodulatory Agent Adherence Trajectories and Survival Among Older Patients With Multiple Myeloma. JCO Oncology Practice 2026, op2500615. PMID: 42081788, DOI: 10.1200/op-25-00615.Peer-Reviewed Original ResearchAltmetricConceptsPoor adherence groupMultiple myelomaAdherence groupIMiD treatmentCox proportional hazards regression modelsCharacteristics associated with adherenceProportional hazards regression modelsSEER-Medicare databaseNon-Hispanic black patientsNon-Hispanic white patientsHazards regression modelsAssociated with adherenceSurvival outcomesRenal failureImmunomodulatory agentsLogistic regression modelsSEER-MedicareOlder patientsWhite patientsBlack patientsBone diseaseGroup 3Comorbidity burdenPatientsComorbid conditionsIP80-11 ASSOCIATION BETWEEN PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING AND INITIAL TREATMENT FOR PROSTATE CANCER AMONG COMMERCIAL INSURANCE BENEFICIARIES
Leapman M, Rothen J, Long J, Kim I, Mitchell A, Yu J, Dinan M, Gross C, Ma X. IP80-11 ASSOCIATION BETWEEN PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING AND INITIAL TREATMENT FOR PROSTATE CANCER AMONG COMMERCIAL INSURANCE BENEFICIARIES. Journal Of Urology 2026, 215: e1589. DOI: 10.1097/01.ju.0001191764.50307.1e.11.Peer-Reviewed Original ResearchSu2107 HELICOBACTER PYLORI INFECTION AND MASLD: A PROSPECTIVE STUDY AND META-ANALYSIS
Zhao L, Chen Y, Zhang X, Mezzacappa C, Ma X, Banini B, Lee J, Liu C, Zhang X, Hsing A, Nguyen M, Hyun C, Camargo M, McGlynn K, Hou L, Taddei T, Zhang X. Su2107 HELICOBACTER PYLORI INFECTION AND MASLD: A PROSPECTIVE STUDY AND META-ANALYSIS. Gastroenterology 2026, 170: s-1557. DOI: 10.1016/s0016-5085(26)03805-9.Peer-Reviewed Original ResearchSu2107 HELICOBACTER PYLORI INFECTION AND MASLD: A PROSPECTIVE STUDY AND META-ANALYSIS
Zhao L, Chen Y, Zhang X, Mezzacappa C, Ma X, Banini B, Lee J, Liu C, Zhang X, Hsing A, Nguyen M, Hyun C, Camargo M, McGlynn K, Hou L, Taddei T, Zhang X. Su2107 HELICOBACTER PYLORI INFECTION AND MASLD: A PROSPECTIVE STUDY AND META-ANALYSIS. Gastrointestinal Endoscopy 2026, 103: s-1557. DOI: 10.1016/s0016-5107(26)03736-3.Peer-Reviewed Original ResearchIP80-14 ASSOCIATION BETWEEN GENOMIC CLASSIFIER SCORES AND INITIAL MANAGEMENT OF LOCALIZED PROSTATE CANCER IN A POPULATION-BASED COHORT IN THE UNITED STATES
Leapman M, Wang R, Sprenkle P, Kim I, Dinan M, Gross C, Ma X. IP80-14 ASSOCIATION BETWEEN GENOMIC CLASSIFIER SCORES AND INITIAL MANAGEMENT OF LOCALIZED PROSTATE CANCER IN A POPULATION-BASED COHORT IN THE UNITED STATES. Journal Of Urology 2026, 215: e1590. DOI: 10.1097/01.ju.0001191764.50307.1e.14.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States
Bewersdorf J, Wang R, Mendez L, Mina A, Aguirre L, Stahl M, Zeidan A, Ma X, Podoltsev N. Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States. Cancer 2026, 132: e70415. PMID: 42033416, DOI: 10.1002/cncr.70415.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyeloproliferative DisordersRetrospective StudiesSulfonamidesTreatment OutcomeUnited StatesConceptsAcute myeloid leukemiaPost-MPN acute myeloid leukemiaLower-intensity therapiesAllo-HCTOverall survivalIntensive chemotherapyMyeloproliferative neoplasmsMyeloid leukemiaPatients treated with intensive chemotherapyProgression to acute myeloid leukemiaComplications of myeloproliferative neoplasmsAllogeneic hematopoietic cell transplantationTreatment of acute myeloid leukemiaMedian overall survivalBCL2 inhibitor venetoclaxHematopoietic cell transplantationEffective bridging therapyOutcomes of patientsInhibitor venetoclaxCurative optionHypomethylating agentsBridging therapyAML patientsCell transplantationTreatment eraTargeted and non-targeted analyses of per-and polyfluoroalkyl substances in newborn dried blood spots and risk of childhood acute lymphoblastic leukemia
Vieira V, Liu S, Morimoto L, Koelmel J, Binczewski N, Wiemels J, Ma X, Godri Pollitt K, Metayer C. Targeted and non-targeted analyses of per-and polyfluoroalkyl substances in newborn dried blood spots and risk of childhood acute lymphoblastic leukemia. Journal Of Exposure Science & Environmental Epidemiology 2026, 1-11. PMID: 41981048, PMCID: PMC13123734, DOI: 10.1038/s41370-026-00891-6.Peer-Reviewed Original ResearchAltmetricConceptsRisk of childhood acute lymphoblastic leukemiaLos Angeles CountyChildhood acute lymphoblastic leukemiaAcute lymphoblastic leukemiaDried Blood SpotsOdds ratioNewborn Dried Blood SpotsElevated riskConfidence intervalsAcute lymphoblastic leukemia riskChildhood ALL riskNon-Hispanic participantsNon-Hispanic childrenStudy of childhood acute lymphoblastic leukemiaPFOS exposureBlood spotsRegistry-based studyEarly life exposuresBirth addressLymphoblastic leukemiaHealth StudyHispanic participantsChildhood cancerStratified analysisBirth year
News
Copy Link
News
- July 17, 2026
Women’s Health Research at Yale Funds Projects on Obesity and Ovarian Aging, Diabetes, Cancers, and Autoimmunity
- April 27, 2026Source: News Medical LIfe Sciences
Early life exposure to PFAS associated with common childhood leukemia
- January 27, 2026
Epidemiologist Dr. Magdalena Cerdá joins YSPH as Chair of the Department of Chronic Disease Epidemiology
- October 28, 2025Source: Yale News
Study Reveals Demographic Disparities in Uptake of Colorectal Cancer Screenings
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Office Fax Number
Mailing Address
Chronic Disease Epidemiology
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
Locations
60 College Street
Academic Office
Ste 406
New Haven, CT 06510